Abstract:

BACKGROUND: The S282T mutation is the main variant described associated with resistance to nucleos(t)ide analogues hepatitis C virus (HCV) NS5B polymerase inhibitors.

OBJECTIVE: We aimed here to investigate whether this substitution pre-existed in treatment naive HCV/HIV-1 coinfected patients.

STUDY DESIGN: NS5B polymerase deep sequencing was performed at a median coverage per base of 4471 in 16 patient samples.

RESULTS: No S282T variant was detected in the 16 analyzed samples.

CONCLUSION: This finding is in agreement with the high genetic barrier of nucleoside analogues NS5B polymerase inhibitors and the clinical efficacy of these compounds.

• Link
• Doi Code: 10.1016/j.jcv.2013.09.022
• IrsiCaixa authors: Sandra Franco, Maria Casadellà , Marc Noguera i Julian, Bonaventura Clotet, Roger Paredes , Miguel Ángel Martínez
• Research group: HIV and HCV Genetic and Phenotypic Variability, Microbial Genomics